<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03392753</url>
  </required_header>
  <id_info>
    <org_study_id>17/LO/1457</org_study_id>
    <nct_id>NCT03392753</nct_id>
  </id_info>
  <brief_title>Mechanochemical Ablation Compared to Cyanoacrylate Adhesive</brief_title>
  <official_title>Randomised Controlled Trial of Mechanochemical Ablation Versus Cyanoacrylate Adhesive for the Treatment of Varicose Veins</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Singapore General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be comparing the treatment of varicose veins using either mechanochemical&#xD;
      ablation (MOCA) or cyanoacrylate adhesive (CAE). Patients will be randomised to receiving&#xD;
      either MOCA or CAE.&#xD;
&#xD;
      The pain scores, clinical scores, quality of life scores, occlusion and re-intervention rate&#xD;
      at 2 weeks, 3, 6 and 12 months as well as the cost effectiveness of each intervention will be&#xD;
      assessed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a randomised clinical trial comparing MOCA to CAE. Patients will be randomised&#xD;
      into group A (MOCA) or group B (CAE). Only the endovenous ablation part of the procedure will&#xD;
      be randomised while the decision as to whether patients should receive treatment of their&#xD;
      varicose tributaries will be at the discretion of the clinical team.&#xD;
&#xD;
      The device used for MOCA (group A) will be the ClariVein® mechanochemical ablation (MOCA)&#xD;
      device (Vascular Insights, Madison, CT, USA).&#xD;
&#xD;
      The device used for CAE (group B) will be the VenaSealTM Closure System (Medtronic,&#xD;
      Minneapolis, Minnesota, USA).&#xD;
&#xD;
      Re-intervention of the treated saphenous veins will not be decided until at least 3 months&#xD;
      after their initial procedure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 6, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Actual">July 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>An internet-based randomisation service will be used Outcome assessors will be blinded as to treatment offered</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Pain score during ablation</measure>
    <time_frame>On day 0</time_frame>
    <description>Pain score during saphenous vein ablation using a 0-100mm visual analogue scale (0=no pain; 100=worst pain)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain score at the end of the procedure</measure>
    <time_frame>On day 0</time_frame>
    <description>Pain score at the end of the procedure using a 0-100mm visual analogue scale (0=no pain; 100=worst pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Generic Quality of life as per EQ-5D Questionnaire</measure>
    <time_frame>12 months</time_frame>
    <description>Using the EuroQoL's EQ-5D questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Specific Quality of life as per the AVVQ</measure>
    <time_frame>12 months</time_frame>
    <description>Using the Aberdeen Varicose Vein Questionnaire (AVVQ) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Specific Quality of life as per the CIVIQ-20</measure>
    <time_frame>12 months</time_frame>
    <description>Using the CIVIQ-20 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical change as per CEAP</measure>
    <time_frame>12 months</time_frame>
    <description>Using the Clinical-Etiological-Anatomical-Pathophysiological (CEAP) classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical change as per VCSS</measure>
    <time_frame>12 months</time_frame>
    <description>Using the Venous Clinical Severity Score (VCSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain score over the first 10 days</measure>
    <time_frame>2 weeks</time_frame>
    <description>Pain score over the first 10 days using a 0-100mm visual analogue scale (0=no pain; 100=worst pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of bruising at 2 weeks</measure>
    <time_frame>2 weeks</time_frame>
    <description>Degree of bruising at 2 weeks using a categorical 0-5 bruising scale (0=no bruising; 5=bruising extending beyond treated segment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to return to normal activities</measure>
    <time_frame>2 weeks</time_frame>
    <description>Length of time in days until normal activities are resumed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occlusion rates</measure>
    <time_frame>12 months</time_frame>
    <description>Rate of occlusion as assessed by duplex ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-intervention rates</measure>
    <time_frame>12 months</time_frame>
    <description>Rate of re-interventional procedures</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Varicose Veins</condition>
  <arm_group>
    <arm_group_label>Mechanochemical ablation (MOCA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mechanochemical ablation using the ClariVein® mechanochemical ablation (MOCA) device (Vascular Insights, Madison, CT, USA).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cyanoacrylate adhesive (CAE)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cyanoacrylate using the VenaSealTM Closure System (Medtronic, Minneapolis, Minnesota, USA).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Mechanochemical ablation</intervention_name>
    <description>Treatment of incompetent saphenous veins using mechanochemical ablation (Clarivein)</description>
    <arm_group_label>Mechanochemical ablation (MOCA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cyanoacrylate adhesive</intervention_name>
    <description>Treatment of incompetent saphenous veins using cyanoacrylate (VenaSealTM)</description>
    <arm_group_label>Cyanoacrylate adhesive (CAE)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults over 18 years of age&#xD;
&#xD;
          -  Symptomatic GSV or SSV vein reflux &gt; 0.5 seconds on colour Duplex&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current DVT&#xD;
&#xD;
          -  Recurrent varicose veins&#xD;
&#xD;
          -  Arterial disease (ABPI&lt;0.8)&#xD;
&#xD;
          -  Vein diameter &lt; 3mm&#xD;
&#xD;
          -  Patient who are unwilling to participate&#xD;
&#xD;
          -  Inability or unwillingness to complete questionnaires&#xD;
&#xD;
          -  Adverse reaction to sclerosant or cyanoacrylate&#xD;
&#xD;
          -  Not been involved in another venous trial for at least 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alun H Davies</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charing Cross Hospital, Imperial College London</name>
      <address>
        <city>London</city>
        <zip>W6 8RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 28, 2017</study_first_submitted>
  <study_first_submitted_qc>January 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 8, 2018</study_first_posted>
  <last_update_submitted>February 9, 2021</last_update_submitted>
  <last_update_submitted_qc>February 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varicose Veins</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>September 23, 2021</submitted>
    <returned>October 20, 2021</returned>
    <submitted>November 1, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

